glp-1 obesity drug news today october 2025 Pipeline Update: November - Prime Therapeutics 1 in 10 Americans Has

Food and Drug Administration (FDA), tirzepatide is gaining attention for its dual-action mechanism as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist

DambrovaMMakrecka-KukaMKukaJVilskerstsRNordbergDAttwoodMMet al

Sometimes people are more responsive to one hormone or another and having a variety of options available would allow a greater number of treatment options. Mir Ali, MD The next step would be to compare the effectiveness of this new medication with ones already on the market and compare cost, Ali added

A.Rodrguez SnchezI

Andrographolide alleviates Parkinsonism in MPTP-PD mice via targeting mitochondrial fission mediated by dynamin-related protein 1